Literature DB >> 25222303

Safety and tolerability of high-dose weekly liposomal amphotericin B antifungal prophylaxis.

Elizabeth O Hand1, Meenakshi R Ramanathan.   

Abstract

Children with hematologic malignancies are at an increased risk of invasive fungal infections and a greater risk has been seen with exposure to building construction. Prophylaxis with high-dose (IV) liposomal amphotericin B (L-AmB) 10 mg/kg once weekly was initiated in our high risk children based on previous pharmacokinetic studies. This treatment regimen was associated with a 26% incidence of adverse infusion reactions.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25222303     DOI: 10.1097/INF.0000000000000335

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  5 in total

1.  Safety, Tolerability, and Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Pediatric Patients.

Authors:  Nita L Seibel; Aziza T Shad; Ihor Bekersky; Andreas H Groll; Corina Gonzalez; Lauren V Wood; Paul Jarosinski; Donald Buell; William W Hope; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

2.  Safety and Efficacy of Intermittent High-Dose Liposomal Amphotericin B Antifungal Prophylaxis in Haemato-Oncology: An Eight-Year Single-Centre Experience and Review of the Literature.

Authors:  Jonathan Youngs; Jen Mae Low; Laura Whitney; Clare Logan; Janice Chase; Ting Yau; Matthias Klammer; Mickey Koh; Tihana Bicanic
Journal:  J Fungi (Basel)       Date:  2020-12-21

Review 3.  Case reports of invasive mucormycosis associated neutropenic enterocolitis in leukemic children: diagnostic and treatment challenges and review of literature.

Authors:  Ali Amanati; Omid Reza Zekavat; Hamidreza Foroutan; Omidreza Azh; Ali Tadayon; Ahmad Monabati; Mohammad Hossein Anbardar; Haleh Bozorgi
Journal:  BMC Infect Dis       Date:  2021-12-20       Impact factor: 3.090

4.  Pediatric Antifungal Prescribing Patterns Identify Significant Opportunities to Rationalize Antifungal Use in Children.

Authors:  Laura Ferreras-Antolín; Adam Irwin; Ayad Atra; Faye Chapelle; Simon B Drysdale; Marieke Emonts; Paddy McMaster; Stephane Paulus; Sanjay Patel; Menie Rompola; Stefania Vergnano; Elizabeth Whittaker; Adilia Warris
Journal:  Pediatr Infect Dis J       Date:  2022-03-01       Impact factor: 2.129

Review 5.  Fungal diseases: could nanostructured drug delivery systems be a novel paradigm for therapy?

Authors:  Aline Raquel Voltan; Guillermo Quindós; Kaila P Medina Alarcón; Ana Marisa Fusco-Almeida; Maria José Soares Mendes-Giannini; Marlus Chorilli
Journal:  Int J Nanomedicine       Date:  2016-08-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.